{
    "2018-10-10": [
        [
            {
                "time": "2018-01-02",
                "original_text": "AbbVie (ABBV) Stock Moves -1.54%: What You Should Know",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "stock moves",
                        "-1.54%"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "Neurocrine Inks Deal with Private Biotech to Make CNS Drugs",
                "features": {
                    "keywords": [
                        "Neurocrine",
                        "deal",
                        "CNS drugs"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "CLASS ACTION UPDATE for ABBV, ALNY and ADNT: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders",
                "features": {
                    "keywords": [
                        "class action",
                        "ABBV",
                        "ALNY",
                        "ADNT"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals",
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "IMPORTANT SHAREHOLDER ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AbbVie Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm",
                "features": {
                    "keywords": [
                        "shareholder alert",
                        "class action lawsuit",
                        "AbbVie"
                    ],
                    "sentiment_score": -0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In AbbVie Inc. (NYSE: ABBV) To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit",
                "features": {
                    "keywords": [
                        "shareholder alert",
                        "Brower Piven",
                        "AbbVie"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "J&J's Stelara Succeeds in Phase III Ulcerative Colitis Study",
                "features": {
                    "keywords": [
                        "J&J",
                        "Stelara",
                        "Phase III",
                        "ulcerative colitis"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "Ex-Dividend Reminder: AbbVie, ConnectOne Bancorp and Pennymac Mortgage Investment Trust",
                "features": {
                    "keywords": [
                        "ex-dividend",
                        "AbbVie",
                        "ConnectOne Bancorp",
                        "Pennymac Mortgage"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals",
                        "financial services"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-02",
                "original_text": "How Novartisâ€™s Sandoz Business Has Been Performing Recently",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Sandoz",
                        "performance"
                    ],
                    "sentiment_score": 0.4,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}